Skip to main content
Fig. 1 | Trials

Fig. 1

From: Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

Fig. 1

Study design of IXION. Hospitalized, non-intubated COVID-19 patients will be included in this study and stratified by WHO score. Patients will then be randomized 2:1 to either FX06 or placebo. FX06 or placebo will be administered intravenously for 5 consecutive days. Patients will be assessed and observed for 28 days and followed up until day 60. SCR screening, BL baseline, FU follow-up, i.v. intravenous, R randomization, WHO World Health Organization. *Day 2–27 will include personal visits as well as remote “visits”

Back to article page

Trials

ISSN: 1745-6215